Daclatasvir
AI444-026
Phase 3 small_molecule completed
Quick answer
Daclatasvir for Hepatitis C Virus Infection is a Phase 3 program (small_molecule) at Bristol-Myers Squibb with 2 ClinicalTrials.gov record(s).
Program details
- Company
- Bristol-Myers Squibb
- Indication
- Hepatitis C Virus Infection
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed